A few years back, a former Goldman Sachs partner stood in front of a room full of hedge fund executives in Miami and told them, with the casual confidence of someone who's already placed his chips, that psychedelics would be the next short-term bubble. He wasn't talking about ayahuasca ceremonies in the Peruvian jungle. He was talking about IPOs, FDA pathways, and patent portfolios. And he was right — sort of.

That moment, more than almost any other, marked the point where psychedelics stopped being a fringe wellness curiosity and became a serious investment category. Compass Pathways did go public. ATAI Life Sciences followed. MindMed listed on the Nasdaq. Billions of dollars poured into research labs trying to figure out how to turn magic mushrooms and ibogaine into prescription medicine. And for people quietly researching whether to book a retreat for their depression, addiction, or grief, this matters more than you might think.

Here's the thing, though. The Wall Street story and the retreat-seeker story are not the same story. They share vocabulary. They sometimes share science. But they're aimed at completely different outcomes, and confusing one for the other can lead you to make a bad decision about your own healing.

Why Investors Suddenly Care About Plant Medicine

The bull case is straightforward. Depression affects hundreds of millions of people globally. Conventional antidepressants help maybe a third of patients meaningfully, and roughly another third get partial relief. That leaves an enormous population — people with treatment-resistant depression, PTSD, addiction, end-of-life anxiety — for whom modern psychiatry has very little to offer. Early clinical trials with psilocybin, MDMA, and ibogaine have produced results that, frankly, look almost too good. Single-digit numbers of sessions producing remission rates that pharmaceutical companies usually dream about.

If you're an investor, that's a market measured in tens of billions. If you're a patient, it's something else entirely — it's the first piece of genuinely new mental health science in fifty years. Both things can be true at once. The awkward part is that they create very different incentives.

Pharmaceutical companies want patentable molecules, controlled dosing, standardized protocols, and reproducible outcomes. They want a pill, or as close to a pill as the FDA will allow. They are not, generally speaking, interested in a Shipibo curandero singing icaros over you for six hours in a wooden maloca. That's a feature, not a bug, of how drug development works. But it does mean the medicalized version of psychedelics that eventually reaches your psychiatrist's office will look almost nothing like a traditional plant medicine retreat.

The Quiet Awakening Around Old Plants

What Novogratz called an awakening — the recognition that ayahuasca, psilocybin mushrooms, and the iboga root from West Africa have real medicinal potential — isn't new to anyone who's spent time in indigenous healing traditions. The Shipibo, the Bwiti, the Mazatec, and dozens of other cultures have known this for centuries. The novelty is that Western institutions like Johns Hopkins and Imperial College London are now publishing the data that confirms what these traditions have always claimed.

This is where master plants come into the conversation. In the Amazonian tradition, plants like ayahuasca, chacruna, bobinsana, and tobacco aren't just chemicals — they're considered teachers, beings with their own intelligence that work with you over time through a structured process called dieta. A retreat-seeker considering ayahuasca needs to understand this framing exists, even if they don't fully buy into it, because the people pouring the brew at most reputable retreats absolutely do.

For addiction recovery in particular, the picture has been quietly remarkable. Ibogaine, derived from the iboga root, has shown the ability to interrupt opioid dependence in ways no pharmaceutical has matched — often in a single, intense session. Ayahuasca centers in Peru and Costa Rica have hosted people fighting alcohol dependence, cocaine addiction, and process addictions with outcomes that, while not formally measured the way a clinical trial would measure them, are striking enough that researchers have started taking them seriously.

What This Means If You're Considering a Retreat

The investment boom is reshaping the retreat landscape in ways most prospective participants don't see. Some changes are good. Some are decidedly not.

On the good side: more public conversation has meant more transparency, better screening protocols at reputable retreats, and a slow professionalization of integration services. Five years ago, finding a therapist who would seriously discuss your ayahuasca experience without recommending an inpatient psych ward was difficult. Now they exist in most major cities. That's progress.

On the less good side: money attracts opportunists. The number of new retreats opening every year has exploded, and not all of them are run by people with the experience, training, or ethics the work requires. I've sat in ceremonies led by maestros with forty years in the tradition, and I've heard horror stories about weekend operators who learned the medicine from a YouTube playlist. The gap between those two ends of the spectrum is enormous and, for an untrained eye, surprisingly hard to spot from a glossy website.

Here's what I'd actually look at when researching a psychedelic retreat:

• Lineage and training of the facilitators. Who taught them? How long did they study? Can they name their teachers? Vague answers are red flags.
• Medical screening before you arrive. Any retreat that takes your deposit without asking about your medications, cardiac history, and family history of psychosis is one I'd walk away from.
• Participant-to-facilitator ratio. Six people per facilitator is workable. Twenty people per facilitator is a circus, not a ceremony.
• Integration support after the retreat. The ceremony is maybe twenty percent of the work. If they hand you a printed booklet and wave goodbye, you're going to struggle.
• Honest discussion of risks and contraindications. If they tell you the medicine is safe for everyone, run.

Cost ranges vary wildly. A week-long ayahuasca retreat in Peru typically runs anywhere from $1,500 at simpler centers to $4,500 at more elaborate ones. Ibogaine clinics, because they require medical supervision, sit higher — usually $5,000 to $10,000 for a treatment program. Psilocybin retreats in the Netherlands, Jamaica, or Costa Rica generally fall between $2,000 and $5,000. None of this is cheap, and the cheap options often aren't the bargain they appear to be.

The Mismatch Between the Clinical Model and the Ceremonial One

One thing the Wall Street narrative tends to flatten is the difference between taking a psychedelic compound in a clinical setting and sitting in ceremony with a plant medicine. Both can be healing. They are not the same experience.

The clinical model, which is what Compass Pathways and similar companies are building toward, looks like this: you arrive at a medical office, take a measured dose of a synthesized molecule, lie on a couch with eyeshades and a curated playlist, and have a trained therapist sit with you. It's regulated, repeatable, and increasingly likely to be covered by insurance. For people with severe treatment-resistant depression who would never set foot in a jungle lodge, this model is going to be a genuine breakthrough.

The ceremonial model is something else. You're typically away from home for a week or more. You eat a restricted diet for days beforehand. You drink the medicine in a group, often through the night, accompanied by songs and prayers that come from a specific cultural tradition. You purge — usually physically, sometimes emotionally, often both. The context, the community, and the cultural container are considered as important as the substance itself.

Neither approach is universally better. They serve different needs. If your goal is to address clinical depression in a structured medical setting, the clinical path may suit you. If your goal is something messier — a confrontation with patterns you can't seem to break, grief you haven't been able to metabolize, a sense that your life has drifted from anything resembling meaning — the ceremonial path tends to do that work in a way no clinic currently replicates.

A Word on the Bubble Question

Was Novogratz right that psychedelics would become a short-term bubble? Partly. Several listed psychedelic companies have had brutal stock performance since their initial euphoria. The science, meanwhile, has continued to mature. MDMA-assisted therapy for PTSD came close to FDA approval and may yet get there. Psilocybin therapy programs are advancing through trials. Ibogaine is finally getting serious clinical attention in the United States after decades of being treated as fringe.

For the retreat-seeker, the financial drama is mostly noise. What matters is that the cultural permission to talk about these experiences is wider than it's ever been, the integration ecosystem is more developed, and the research validating what indigenous traditions have long claimed continues to accumulate. None of that guarantees a good experience for you personally. But it does mean you're not stepping into the unknown alone the way someone in 1995 would have been.

If something in this piece has nudged you closer to actually doing the work rather than just reading about it, a curated selection of ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine, whichever one you choose, will still be there when you're ready.